Bamlanivimab prophylaxis reduces hospitalisation and mortality: results from phase 3 BLAZE-2 study
Simon Collins, HIV i-Base
The BLAZE-2 study randomised 1175 residents or staff who were at high risk of COVID-19 through living or working in residential care homes to either bamlanivimab or placebo.
Of these, 966/1175 were PCR negative, using bamlanivimab as prophylaxis and 209/1175 were PCR positive, using the intervention as treatment.
Participants in the prevention group needed to be PCR negative at baseline with a primary endpoint of incidence of COVID-19 symptoms and secondary endpoint of PCR-positive transmission, both at day 57.
Full results presented at CROI 2021 showed an 80% reduced risk of symptoms: OR 0.20 (95%CI: 0.08 to 0.49), p<0.001.
The top line results from this study had been released in a company press statement in January. 
- Cohen M et al. Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-home setting. CROI 2021, virtual. Oral abstract 121.
- Bamlanivimab (LY-CoV555) prophylaxis prevents COVID-19 in care homes: results of BLAZE-2 study. HTB (24 February 2021).
This report was first published on 19 March 2021.